Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Uracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.71 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uracil SCHEMBL4652740 | 0.98 | CRBN (0.74) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL479740 | 0.98 | CRBN (0.74) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL27284298 | 0.89 | CRBN (0.61) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL9429688 | 0.87 | CRBN (0.77) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL25208560 | 0.86 | CRBN (0.63) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL27509565 | 0.86 | CRBN (0.68) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL27495406 | 0.86 | CRBN (0.68) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL27799965 | 0.84 | CRBN (0.90) | CRBNMMP2TP53ALDH1A1LMNA | |
| Uracil SCHEMBL11607890 | 0.84 | — | — | |
| Uracil SCHEMBL8235 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235122-B1 | MAGENTA RECORDING INK COMPOSITION, INKJET RECORDING METHOD, AND INK RECORDED MATTER | RICOH CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| CN-101925661-B | Magenta recording ink composition, ink jet recording method and ink recorded matter | RICOH KK | 2013-09-25 | — | — | CN | disclosed |
| US-8523992-B2 | Magenta recording ink composition, inkjet recording method, and ink recorded matter | RICOH COMPANY, LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| CN-101925661-A | Magenta recording ink composition, ink jet recording method and ink recorded matter | RICOH KK | 2010-12-22 | — | — | CN | disclosed |
| US-20100285287-A1 | MAGENTA RECORDING INK COMPOSITION, INKJET RECORDING METHOD, AND INK RECORDED MATTER | RICOH COMPANY, LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2235122-A1 | MAGENTA RECORDING INK COMPOSITION, INKJET RECORDING METHOD, AND INK RECORDED MATTER | Ricoh Company, Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009093721-A1 | MAGENTA RECORDING INK COMPOSITION, INKJET RECORDING METHOD, AND INK RECORDED MATTER | RICOH COMPANY, LTD. (JP) | 2009-07-30 | — | — | WO | disclosed |